Symbiotec Pharmalab stands out as the preferred long-term pick, backed by SBI Securities' 'Subscribe' rating and Master Capital's positive view on its specialised business.
Market Samachar is a news aggregator. This article was originally published by Share Market Today. Tap the button above to read the full story on their site.